Drugs / Inpegsomatropin
Inpegsomatropin
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT07551804 | May 2026 → Dec 2027 expected | pituitary deficiency | Xiamen Amoytop Biotech Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT07614152 | Jun 2026 → Mar 2028 expected | Turner syndrome | Xiamen Amoytop Biotech Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07309562 | Jan 2026 → Mar 2028 expected | fetal growth restriction | Xiamen Amoytop Biotech Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06927310 | Apr 2025 → Mar 2026 overdue | isolated short stature | Xiamen Amoytop Biotech Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Inpegsomatropin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07551804 ↗ |
| Known as | Inpegsomatropina | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314747 ↗ |
| Known as | Inpegsomatropine | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314747 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL5314747 ↗ |
| Route | Subcutaneous | “Inpegsomatropin injection, 280 μg/kg/week, s.c., once weekly” NCT06927310 ↗ |